A US federal judge declares a mistrial in Masimo's lawsuit against Apple over Apple Watch stolen trade secret claims, after jurors failed to reach a consensus
Context & Ripple Effects
The hung jury left Masimo’s trade-secret allegations against Apple unresolved rather than establishing a factual or legal winner. It sits within a broader Apple Watch dispute that later produced a $250 design-patent award for Apple against Masimo.
The companies’ conflict spans different IP theories and products: later coverage also records a $634M jury award against Apple over a Masimo blood-oxygen patent, which Apple said it would appeal. This mistrial shows why any single verdict is an incomplete measure of leverage in the dispute.
First-order effects
- Masimo does not obtain a trade-secret verdict or damages from this trial, while Apple avoids an adverse judgment on these claims for now.
- The case remains unresolved after jurors could not agree, preserving the parties’ litigation burden and uncertainty around the allegations.
Second-order effects
- Neither company can treat this proceeding as a decisive negotiating or product-strategy win; the separate design- and blood-oxygen-patent cases keep the dispute multi-front.
- The outcome reinforces the practical distinction between trade-secret claims and patent claims: the same commercial rivalry can produce materially different legal outcomes across cases.
Third-order effects
- If this pattern persists, wearable-health competition will increasingly be shaped by overlapping litigation tracks—talent and trade-secret allegations alongside patents—rather than a single dispositive case.
- For device makers and medical-technology specialists, recruiting and technical collaboration may require more formal controls over confidential know-how as product categories converge.
The trend: The Apple–Masimo conflict is one instance of wearable-health competition moving from product differentiation into layered disputes over talent, confidential know-how, and patents.